Management ChangeJul 20, 2026, 04:08 PM
Rani Therapeutics Grants 2M Stock Options to New CFO Maestas
AI Summary
Rani Therapeutics granted an equity award in the form of a stock option to purchase 2,000,000 shares of its Class A common stock to Nicholas Maestas, the company's new Chief Financial Officer. This award, granted on July 17, 2026, serves as an inducement for his employment. The stock option has an exercise price of $0.6973 per share and vests over four years, subject to continued service.
Key Highlights
- Granted stock option for 2,000,000 shares of Class A common stock.
- Awarded to Nicholas Maestas, the new Chief Financial Officer.
- Grant date was July 17, 2026.
- Exercise price set at $0.6973 per share.
- Option has a ten-year term.
- Vests over four years, with 25% on first anniversary of employment.
Price Impact
More from RANI